Bial - Portela C S.A.: all 139 studies

Page 2 of 2. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058CompletedNCT03708146Phase 1
• Effect of BIA 5 1058 on Cardiac RepolarizationCompletedNCT03489005Phase 1
• Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067CompletedNCT03119194Phase 1
• Bioequivalence of Two Different Sources of Eslicarbazepine AcetateCompletedNCT03116321Phase 1
• Effect of Food on OpicaponeCompletedNCT03116308Phase 1
• Bioavailability and Bioequivalence Study of Two Different Sources of OpicaponeCompletedNCT03116295Phase 1
• Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" PhenomenonCompletedNCT03103399Phase 2
• Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453CompletedNCT03099226Phase 1
• Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mgCompletedNCT03097211Phase 1
• Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young SubjectsCompletedNCT03095105Phase 1
• Effect of Food on BIA 6-512 (Trans-resveratrol)CompletedNCT03095092Phase 1
• Effect of BIA 6-512 at Steady-state on the Levodopa PharmacokineticsCompletedNCT03094156Phase 1
• Tolerability and Steady-state Pharmacokinetics of BIA 6-512CompletedNCT03093389Phase 1
• Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa PharmacokineticsCompletedNCT03091868Phase 1
• Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa PharmacokineticsCompletedNCT03091543Phase 1
• Pharmacokinetics of BIA 5-453 and Its MetabolitesCompletedNCT03090724Phase 1
• Bioavailability Study of BIA 5-453CompletedNCT03090568Phase 1
• Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and MetabolitesCompletedNCT03014375Phase 1
• Efficacy and Safety of Opicapone in Clinical PracticeCompletedNCT02847442Phase 4
• Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453CompletedNCT02845037Phase 1
• Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453CompletedNCT02840565Phase 1
• Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease PatientsCompletedNCT02834507Phase 2
• Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of WarfarinCompletedNCT02779348Phase 1
• Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/BenserazideCompletedNCT02778594Phase 1
• Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy VolunteersCompletedNCT02777671Phase 1
• Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/CarbidopaCompletedNCT02774564Phase 1
• Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202CompletedNCT02772627Phase 1
• Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and MetabolitesCompletedNCT02772614Phase 1
• Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)CompletedNCT02763852Phase 1
• Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)CompletedNCT02763839Phase 1
• Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202CompletedNCT02763800Phase 1
• Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202CompletedNCT02763787Phase 1
• Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset SeizuresCompletedNCT02484001Phase 3
• Effect of Opicapone at Steady State on Warfarin PharmacokineticsCompletedNCT02305030Phase 1
• Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine.CompletedNCT02283801Phase 1
• The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in PatientsTerminatedNCT01878578Phase 1
• Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)CompletedNCT01532726
• Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and WomenCompletedNCT01532115Phase 1
• Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset SeizuresCompletedNCT01162460Phase 3

← Bial - Portela C S.A. overview and focus areas